Advertisement

Acta Diabetologica

, Volume 48, Issue 3, pp 197–202 | Cite as

Excess mortality in middle-aged men with diabetes aged 15–34 years at diagnosis

  • Carina TörnEmail author
  • Sofie Ingemansson
  • Ulf Lindblad
  • Soffia Gudbjörnsdottir
  • on behalf of the DISS study group
Original Article

Abstract

The aim of this study is to assess mortality risk and the excess of risk in patients with diabetes. Patients were 15–34 years old at diagnosis of diabetes mellitus (n = 879) in 1992 and 1993 in this national cohort from Sweden. Healthy controls were matched for gender and birth on the same day as the index cases (n = 837). The civic registration number was used to link patients and controls to the Swedish Cause of Death Registry. During follow-up, 3.3% (29/879) of patients and 1.1% (9/837; P = 0.002) of controls died. The risk for a patient with diabetes to die was almost threefold increased compared with healthy controls; hazard ratio, 2.9 (95% CI 1.4–6.2). This increased risk was significant in men; hazard ratio, 2.8 (95% CI 1.2–6.5). Diabetes as the underlying cause of death accounted for 38% (11/29) of deaths among patients. Most patients, 55% (16/29), died at home, remaining patients in hospital, 28% (8/29), or elsewhere 17% (5/29) compared to controls of whom 33% (3/9; P = 0.45) died at home, 33% (3/9; P = 1.0) in hospital, and 33% (3/9; P = 0.36) elsewhere. Only 55% (16/29) of patients had a specified day of death on death certificates compared to 100% (9/9; P = 0.016) of controls. Adult men with diabetes had an almost threefold increased risk to die within 15 years of diagnosis compared to healthy men. Most middle-aged patients with diabetes died at home and often without a specified date of death recorded.

Keywords

Mortality Natural history Risk analysis Retrospective case–control study 

Notes

Acknowledgments

This study was funded by The Crafoord Foundation, Lund, Sweden by a research grant (20080671) to CT. The present members of the DISS-study group are Hans Arnquist, Linköping, Jan Bolinder, Stockholm, Mona Landin-Olsson, Lund, Olov Rolandsson, Umeå, Soffia Gudbjörnsdottir (President), Gothenburg and Lennarth Nyström, Umeå. The baseline study from onset of diabetes and the first 6 years of disease with yearly blood sampling as well as the matched control study was funded by National Institutes of Health, NIH grant DK 42,654 to Åke Lernmark, Malmö, Sweden. Abstracts of less than 300 words were submitted to the 45th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD) 6–8 May 2010 and to the 46th EASD Annual Meeting 20–24 September 2010.

Conflict of interest statement

The authors of this manuscript declare no conflicts of interests.

References

  1. 1.
    Wibell L, Nystrom L, Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, Sundkvist G (2001) Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15–34 years old at diagnosis. J Intern Med 249:263–270PubMedCrossRefGoogle Scholar
  2. 2.
    Dahlquist G, Kallen B (2005) Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 28:2384–2387PubMedCrossRefGoogle Scholar
  3. 3.
    Waernbaum I, Blohme G, Ostman J, Sundkvist G, Eriksson JW, Arnqvist HJ, Bolinder J, Nystrom L (2006) Excess mortality in incident cases of diabetes mellitus aged 15-34 years at diagnosis: a population-based study (DISS) in Sweden. Diabetologia 49:653–659PubMedCrossRefGoogle Scholar
  4. 4.
    Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G (2006) Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 49:298–305PubMedCrossRefGoogle Scholar
  5. 5.
    Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, Schober E, Gyurus E, Castell C, Urbonaite B, Rosenbauer J, Iotova V, Thorsson AV, Soltesz G (2007) Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 50:2439–2442PubMedCrossRefGoogle Scholar
  6. 6.
    Asao K, Sarti C, Forsen T, Hyttinen V, Nishimura R, Matsushima M, Reunanen A, Tuomilehto J, Tajima N (2003) Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 26:2037–2042PubMedCrossRefGoogle Scholar
  7. 7.
    Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC (2003) Mortality from heart disease in a cohort of 23, 000 patients with insulin-treated diabetes. Diabetologia 46:760–765PubMedCrossRefGoogle Scholar
  8. 8.
    Green A, Borch-Johnsen K, Andersen PK, Hougaard P, Keiding N, Kreiner S, Deckert T (1985) Relative mortality of type 1 (insulin-dependent) diabetes in Denmark: 1933–1981. Diabetologia 28:339–342PubMedCrossRefGoogle Scholar
  9. 9.
    Sartor G, Nystrom L, Dahlquist G (1991) The Swedish Childhood Diabetes Study: a seven-fold decrease in short-term mortality? Diabet Med 8:18–21PubMedCrossRefGoogle Scholar
  10. 10.
    Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619–4623PubMedCrossRefGoogle Scholar
  11. 11.
    Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G, Bjork E, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G, Lernmark A (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447PubMedCrossRefGoogle Scholar
  12. 12.
    Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G (2001) Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33:115–120PubMedCrossRefGoogle Scholar
  13. 13.
    Diabetes Mellitus (1985) Report of a WHO study group. Technical report series No 727, Geneva. Google Scholar
  14. 14.
    Littorin B, Sundkvist G, Schersten B, Nystrom L, Arnqvist HJ, Blohme G, Lithner F, Wibell L, Ostman J (1996) Patient administrative system as a tool to validate the ascertainment in the diabetes incidence study in Sweden (DISS). Diabetes Res Clin Pract 33:129–133PubMedCrossRefGoogle Scholar
  15. 15.
    Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666PubMedCrossRefGoogle Scholar
  16. 16.
    Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31:1360–1366PubMedCrossRefGoogle Scholar
  17. 17.
    Tu E, Twigg SM, Duflou J, Semsarian C (2008) Causes of death in young Australians with type 1 diabetes: a review of coronial post-mortem examinations. Med J Aust 188:699–702PubMedGoogle Scholar
  18. 18.
    Ostgren CJ, Lindblad U, Melander A, Rastam L (2002) Survival in patients with type 2 diabetes in a Swedish community: Skaraborg hypertension and diabetes project. Diabetes Care 25:1297–1302PubMedCrossRefGoogle Scholar
  19. 19.
    Grauslund J, Jorgensen TM, Nybo M, Green A, Rasmussen LM, Sjolie AK (2009) Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. J Diabetes Complicat 24:223–228PubMedCrossRefGoogle Scholar
  20. 20.
    Krishnan S, Short KR (2009) Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr 4:50–56PubMedCrossRefGoogle Scholar
  21. 21.
    Futh R, Dinh W, Bansemir L, Ziegler G, Bufe A, Wolfertz J, Scheffold T, Lankisch M (2009) Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure? Acta Diabetol 46:335–338PubMedCrossRefGoogle Scholar
  22. 22.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMedCrossRefGoogle Scholar
  23. 23.
    Wit MA, de Mulder M, Jansen EK, Umans VA (2010) Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol [Epub ahead of print] PubMed PMID: 20857149Google Scholar
  24. 24.
    May O, Arildsen H (2011) Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol 48:55–59Google Scholar
  25. 25.
    Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87–95PubMedCrossRefGoogle Scholar
  26. 26.
    Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D’Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371PubMedCrossRefGoogle Scholar
  27. 27.
    Federici M, Petrone A, Porzio O, Bizzarri C, Lauro D, D’Alfonso R, Patera I, Cappa M, Nistico L, Baroni M, Sesti G, di Mario U, Lauro R, Buzzetti R (2003) The Gly972– > Arg IRS-1 variant is associated with type 1 diabetes in continental Italy. Diabetes 52:887–890PubMedCrossRefGoogle Scholar
  28. 28.
    Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G (2004) Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89:3606–3609PubMedCrossRefGoogle Scholar
  29. 29.
    Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R (2004) The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27:1394–1398PubMedCrossRefGoogle Scholar
  30. 30.
    Chida Y, Hamer M (2008) An association of adverse psychosocial factors with diabetes mellitus: a meta-analytic review of longitudinal cohort studies. Diabetologia 51:2168–2178PubMedCrossRefGoogle Scholar
  31. 31.
    Helgeson VS, Reynolds KA, Escobar O, Siminerio L, Becker D (2007) The role of friendship in the lives of male and female adolescents: does diabetes make a difference? J Adolesc Health 40:36–43PubMedCrossRefGoogle Scholar
  32. 32.
    Littorin B, Sundkvist G, Nystrom L, Carlson A, Landin-Olsson M, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson JW, Schersten B, Wibell L (2001) Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study. Diabetes Care 24:1033–1037PubMedCrossRefGoogle Scholar
  33. 33.
    Tattersall RB, Gill GV (1991) Unexplained deaths of type 1 diabetic patients. Diabet Med 8:49–58PubMedCrossRefGoogle Scholar
  34. 34.
    Sartor G, Dahlquist G (1995) Short-term mortality in childhood onset insulin-dependent diabetes mellitus: a high frequency of unexpected deaths in bed. Diabet Med 12:607–611PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Carina Törn
    • 1
    Email author
  • Sofie Ingemansson
    • 1
  • Ulf Lindblad
    • 2
  • Soffia Gudbjörnsdottir
    • 3
  • on behalf of the DISS study group
  1. 1.Unit for Diabetes and Celiac Disease, Wallenberg Laboratory, Skåne University HospitalLund UniversityMalmöSweden
  2. 2.Department of Primary Health CareUniversity of GothenburgGothenburgSweden
  3. 3.NHVThe Nordic Research Academy for Global HealthGothenburgSweden

Personalised recommendations